swish30

ATNM: Potential turning point ahead of Phase 2 results

看多
AMEX:ATNM   Actinium Pharmaceuticals, Inc. (Delaware)
Immuno-oncology stock that has recently completed an offering of common stock @ $0.75 per share. Stock looks to have bottomed out. Buy a for a potential 10-20% bounce.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。